Vedolizumab as a first-line biologic for Crohn's?
About one patient in eight experiences endoscopic remission of Crohn's disease after completing 26 weeks of treatment with the gut-selective monoclonal antibody vedolizumab, a study shows.
In the phase 3b open-label VERSIFY study, sponsored by Takeda Pharmaceuticals, the biologic was tested in 101 patients with moderately-to-severely active Crohn's disease.
Twelve patients achieved the primary endpoint of endoscopic remission (defined as a Simple Endoscopic Score for Crohn's of four or less) at week 26.
"(These) data are in line with other biologics,"